Key intermediates for production of selective PI3K inhibitor
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 上海厚博生物科技有限公司
- Publication Date
- 2018-03-13
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of pharmacy, in particular to a series of key intermediates for producing selective PI3K inhibitors. Background technique
[0002] 5-[2,6-bis(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinylamine is a selective PI3K inhibitor developed by pharmaceutical giant Novartis, English The name is Buparlisib, code-named BKM120 or NVP-BKM120. BKM120 has anti-proliferative activity when acting on cell lines deregulated by PI3K, including A2780, U87MG, MCF7 and DU145, with GI50 of 0.1-0.7nM (Burger MT, et al.ACS Med Chem Lett, 2011,2(10), 774–779). BKM120 induces apoptosis in multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266), resulting in increased G1 phase cells and decreased S phase cells. BKM120 induces apoptosis in CD138+ primary MM cells and is less toxic to CD138- stromal cells. BKM120 can cause upregulation of BimS and downregulation of XIAP. (Zheng Y, et al. J Mol Med (Berl), 2011 Dec 30.) BKM120...